Edge Therapeutics Inc. (EDGE)’s Financial Results Comparing With Rexahn Pharmaceuticals Inc. (NYSEAMERICAN:RNN)

Edge Therapeutics Inc. (NASDAQ:EDGE) and Rexahn Pharmaceuticals Inc. (NYSEAMERICAN:RNN) compete against each other in the Biotechnology sector. We will compare them and contrast their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Edge Therapeutics Inc. N/A 0.00 N/A -1.31 0.00
Rexahn Pharmaceuticals Inc. N/A 0.00 14.37M -0.47 0.00

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for Edge Therapeutics Inc. and Rexahn Pharmaceuticals Inc.


Table 2 provides the return on equity, net margins and return on assets of the two firms.

Net Margins Return on Equity Return on Assets
Edge Therapeutics Inc. 0.00% -118.1% -82.7%
Rexahn Pharmaceuticals Inc. 0.00% -119.8% -71.6%

Risk & Volatility

A 3.67 beta means Edge Therapeutics Inc.’s volatility is 267.00% more than S&P 500’s volatility. Rexahn Pharmaceuticals Inc.’s 30.00% less volatile than S&P 500 volatility due to the company’s 0.7 beta.


Edge Therapeutics Inc.’s Current Ratio is 5.6 while its Quick Ratio is 5.6. On the competitive side is, Rexahn Pharmaceuticals Inc. which has a 4.1 Current Ratio and a 4.1 Quick Ratio. Edge Therapeutics Inc. is better positioned to pay off short and long-term obligations compared to Rexahn Pharmaceuticals Inc.

Insider & Institutional Ownership

The shares of both Edge Therapeutics Inc. and Rexahn Pharmaceuticals Inc. are owned by institutional investors at 28.2% and 9.3% respectively. Insiders owned 11.39% of Edge Therapeutics Inc. shares. Competitively, Rexahn Pharmaceuticals Inc. has 0.2% of it’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Edge Therapeutics Inc. 14.43% 4.52% -11.61% -45.89% -96.93% 43.27%
Rexahn Pharmaceuticals Inc. 3.48% -16.3% -51.51% -67.96% -65.28% -42.13%

For the past year Edge Therapeutics Inc. had bullish trend while Rexahn Pharmaceuticals Inc. had bearish trend.


Edge Therapeutics Inc. beats on 4 of the 6 factors Rexahn Pharmaceuticals Inc.

Edge Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and seeks to commercialize hospital-based therapies for acute life-threatening neurological and other conditions. Its lead product includes EG-1962, a polymer-based microsphere used for the treatment of aneurysmal subarachnoid hemorrhage. The company is also developing EG-1964 for the management of chronic subdural hematoma as a prophylactic treatment to prevent recurrent bleeding on the surface of the brain. Edge Therapeutics, Inc. was founded in 2009 and is headquartered in Berkeley Heights, New Jersey.

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer. The companyÂ’s clinical stage drug candidates include RX-3117, which is in Phase IIa clinical trial for the treatment of patients with relapsed or refractory pancreatic cancer and advanced bladder cancer; and Supinoxin that is in Phase IIa clinical study to treat patients with metastatic triple negative breast cancer. It is also developing Archexin, which has completed a pilot Phase IIa clinical trial for the treatment of pancreatic cancer; and is in Phase IIa clinical trial to treat patients with metastatic renal cell carcinoma. In addition, the company is involved in developing RX-21101, an N-(2-Hydroxypropyl) methacrylamide-docetaxel-folate, which is in pre-clinical development stage used for the treatment of tumors. Rexahn Pharmaceuticals, Inc. is headquartered in Rockville, Maryland.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.